2018/04/18 by Alexis A. Thompson, Mark C. Walters, Janet Kwiatkowski +54 · 3 citations
Medicine · #Hemoglobinopathies and Related Disorders #Erythrocyte Function and Pathophysiology #Parvovirus B19 Infection Studies
paper · pdf · doi:10.1056/nejmoa1705342
BACKGROUND: ) gene could substitute for long-term red-cell transfusions in a patient with β-thalassemia, we wanted to evaluate the safety and efficacy of such gene therapy in patients with transfusion-dependent β-thalassemia. METHODS: , transfusion requirements, and average vector copy number. RESULTS: genotype or two copies of the IVS1-110 mutation, the median annualized transfusion volume was decreased by 73%, and red-cell transfusions were discontinued in 3 patients. Treatment-related adverse events were typical of those associated with autologous stem-cell transplantation. No clonal dominance related to vector integration was observed. CONCLUSIONS: Gene therapy with autologous CD34+ cells transduced with the BB305 vector reduced or eliminated the need for long-term red-cell transfusions in 22 patients with severe β-thalassemia without serious adverse events related to the drug product. (Funded by Bluebird Bio and others; HGB-204 and HGB-205 ClinicalTrials.gov numbers, NCT01745120 and NCT02151526 .).